Search results for "azithromycin"

showing 10 items of 26 documents

Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster

2016

The abrupt onslaught of the syphilis pandemic that started in the late fifteenth century established this devastating infectious disease as one of the most feared in human history1 . Surprisingly, despite the availability of effective antibiotic treatment since the mid-twentieth century, this bacterial infection, which is caused by Treponema pallidum subsp. pallidum (TPA), has been re-emerging globally in the last few decades with an estimated 10.6 million cases in 2008 (ref. 2). Although resistance to penicillin has not yet been identified, an increasing number of strains fail to respond to the secondline antibiotic azithromycin3. Little is known about the genetic patterns in current infec…

0301 basic medicineMicrobiologia340 LawCiencias de la SaludAzithromycinGlobal HealthBacterisApplied Microbiology and Biotechnology2726 Microbiology (medical)1307 Cell BiologyGenotypePandemicPhylogenyMolecular EpidemiologyTreponemaPhylogenetic treebiology2404 Microbiology10177 Dermatology ClinicTREPONEMA PALLIDUM10218 Institute of Legal MedicineAnti-Bacterial Agents3. Good health590 Animals (Zoology)//purl.org/becyt/ford/3 [https]ORIGIN OF SYPHILISMalalties de transmissió sexualDNA BacterialMicrobiology (medical)CIENCIAS MÉDICAS Y DE LA SALUDGenotypeImmunology610 Medicine & healthMicrobiologyEvolution Molecular//purl.org/becyt/ford/3.3 [https]10127 Institute of Evolutionary Biology and Environmental Studies03 medical and health sciences1311 GeneticsPhylogeneticsDrug Resistance BacterialGeneticsmedicine2402 Applied Microbiology and BiotechnologyHumansSyphilisTreponema pallidumPandemics2403 ImmunologyMolecular epidemiologyGenetic VariationSequence Analysis DNACell Biologymedicine.diseasebiology.organism_classificationVirologyEnfermedades Infecciosas030104 developmental biologyInfectious disease (medical specialty)570 Life sciences; biologySyphilisGenome Bacterial
researchProduct

Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study.

2021

Abstract Objectives Gonococcal infection is one of the most reported sexually transmitted infections and antimicrobial resistance in Neisseria gonorrhoeae (NG) is challenging for the treatment of this infection. This observational study aimed to describe antimicrobial resistance of NG and epidemiological data from patients with gonococcal infection in eight regions of Spain, for updating the local therapeutic guidelines. Methods MICs of penicillin, cefixime, ceftriaxone, azithromycin, ciprofloxacin, fosfomycin and gentamicin were determined by Etest for all NG isolates recovered from 1 April 2018 to 30 September 2019 from 10 hospitals in Spain. Resistance determinants were identified using …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialty030106 microbiologyMicrobial Sensitivity TestsFosfomycinAzithromycinAzithromycinmedicine.disease_cause03 medical and health sciencesGonorrheaSexual and Gender Minorities0302 clinical medicineAntibiotic resistanceCiprofloxacinInternal medicineDrug Resistance BacterialmedicineHumansPharmacology (medical)030212 general & internal medicineProspective StudiesHomosexuality MaleEtestPharmacologybusiness.industryCeftriaxoneNeisseria gonorrhoeaeAnti-Bacterial AgentsPenicillinCiprofloxacinInfectious DiseasesSpainNeisseria gonorrhoeaebusinessCefiximemedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Computational analysis of macrolides as SARS-CoV-2 main protease inhibitors: a pattern recognition study based on molecular topology and validated by…

2021

Since the outbreak of the current SARS-CoV-2 pandemic, much has been discussed about the effectiveness of treatments based on hydroxychloroquine combined with azithromycin or another macrolide. However, few articles have dealt with the possibility of using macrolides alone in treating the disease. In the present article, the authors' hypothesis centers on the possibility that macrolides are effective against SARS-CoV-2 by inhibiting the virus protease. In support of this hypothesis, significant results are collected by following an in silico strategy based on a combination of molecular topology and docking. The results are in accordance with recent clinical data generated during the pandemi…

0301 basic medicineProteaseChemistryIn silicomedicine.medical_treatmentGeneral ChemistryComputational biologyAzithromycinFlurithromycinCatalysisVirus03 medical and health sciences030104 developmental biology0302 clinical medicineDocking (molecular)030220 oncology & carcinogenesisClarithromycinMaterials ChemistrymedicineViral loadmedicine.drugNew Journal of Chemistry
researchProduct

Viral exanthema as manifestation of SARS-CoV-2 infection

2020

Abstract Rationale: The clinical manifestations of the SARS-CoV-2 infection are mainly respiratory but the virus can cause a variety of symptoms. Dermatological findings are less well-characterized. Data is scarce on their timing, type and correlation with the immune response. Patient concerns: We present the case of SARS-CoV-2 infection in a previously healthy woman who presented with respiratory symptoms and developed anosmia, diarrhea, and an erythematous maculo-papular rash on day 15 from symptom onset. Diagnosis: The nasopharyngeal swab tested by real time PCR for COVID-19 was positive. We interpreted this as a viral exanthema likely caused by an immune response to SARS-CoV-2 nucleotid…

Administration TopicalvirusesAzithromycinAzithromycinLopinavirimmune responseCOVID-19 Testing0302 clinical medicine030212 general & internal medicineclinical manifestations4900virus diseasesLopinavirGeneral MedicineRashDrug CombinationsDiarrheaTreatment Outcome030220 oncology & carcinogenesisFemaleSymptom Assessmentmedicine.symptomCoronavirus InfectionsHydroxychloroquineResearch Articlemedicine.drugAdultmedicine.medical_specialtyPneumonia ViralAnosmiaAntiviral AgentsBetacoronavirus03 medical and health sciencesImmune systemImmunitymedicineHumansClinical Case ReportGlucocorticoidsPandemicsRitonavirClinical Laboratory TechniquesSARS-CoV-2business.industryfungiCOVID-19HydroxychloroquineExanthemabiochemical phenomena metabolism and nutritionDermatologybusinessanosmiaMedicine
researchProduct

Epidemiology and clinical features of Mediterranean spotted fever in Italy

2006

Mediterranean Spotted Fever is caused by Rickettsia conorii and is transmitted to humans by Rhipicephalus sanguineus, the common dog tick. It is characterized by the symptomatologic triad: fever, exanthema and "tache noire", the typical eschar at the site of the tick bite. In Italy the most affected region is Sicily. The seasonal peak of the disease (from June through September) occurs during maximal activity of immature stage ticks. Severe forms of the disease have been reported in 6% of patients, especially adults with one of the following conditions: diabetes, cardiac disease, chronic alcoholism, glucose-6-phosphate dehydrogenase deficiency, end stage kidney disease. The mortality rate m…

AdultAlanine TransaminaseComorbidityRhipicephalus sanguineusSpotted Fever boutonneuse fever Rickettsia clarithromycin azithromycinBoutonneuse FeverThrombocytopeniaAnti-Bacterial AgentsRickettsia conoriiItalyAnimalsHumansKidney Failure ChronicArachnid VectorsAspartate AminotransferasesBites and StingsSeasonsChild
researchProduct

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

2017

Summary Background Lyme borreliosis develops in 1–5% of individuals bitten by ticks, but with a diagnostic gap affecting up to 30% of patients, a broadly applicable pharmacological prevention strategy is needed. Topical azithromycin effectively eradicated Borrelia burgdorferi sensu lato from the skin in preclinical studies. We assessed its efficacy in human beings. Methods In this randomised, double-blind, placebo-controlled, multicentre trial done in 28 study sites in Germany and Austria, adults were equally assigned to receive topical 10% azithromycin or placebo twice daily for 3 consecutive days, within 72 h of a tick bite being confirmed. Randomisation numbers, which were stratified by …

AdultMale0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationAzithromycinAzithromycinPlacebolaw.invention03 medical and health sciencesTicksDouble-Blind MethodRandomized controlled triallawGermanyInternal medicinemedicineClinical endpointAnimalsHumansTreatment FailureSeroconversioneducationLyme Diseaseeducation.field_of_studybusiness.industryAntibiotic ProphylaxisMiddle Agedbacterial infections and mycosesAnti-Bacterial AgentsSurgeryClinical trialInfectious DiseasesBorrelia burgdorferiErythema migransFemalebusinessmedicine.drugThe Lancet Infectious Diseases
researchProduct

Antibacterial susceptibility patterns of Porphyromonas gingivalis isolated from chronic Periodontitis patients

2010

Objectives: To test the antimicrobial sensitivity of Porphyromonas gingivalis to a panel of eight orally administrable antibiotics in chronic periodontal diseases and to evaluate factors associated with periodontitis in adult patients. Study Design: A total of fifty strains of P. gingivalis were isolated from one hundred and twenty adult patients with chronic perio-dontitis. Identification of bacteria was carried out by anaerobic culture and biochemical tests. Selected colonies of P. gingivalis were used to evaluate the antibacterial activities of penicillin, metronidazole, amoxicillin, amoxicillin/clavulanic acid, clindamycin, doxy-cycline, ciprofloxacin and azithromycin. Results: Most of …

AdultMalemedicine.drug_classAntibioticsAdministration OralMicrobial Sensitivity TestsAzithromycinMicrobiologyClavulanic acidmedicineHumansPeriodontitisGeneral DentistryPorphyromonas gingivalisPeriodontitisbiologybusiness.industryMiddle AgedAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseasebiology.organism_classificationChronic periodontitisAnti-Bacterial AgentsCiprofloxacinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASChronic DiseaseFemaleSurgerybusinessPorphyromonas gingivalismedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Neglected diseases caused by bacterial infections.

2009

Bacterial infections represent a major health problem, especially in third world countries. In endemic regions, large populations of people are greatly affected, but the medical care is very limited. In this review, the neglected diseases buruli ulcer and trachoma are elucidated. Buruli ulcer is caused by Mycobacterium ulcerans which produces an outstanding immunosuppressive toxin mycolactone that induces an ulcerative, necrotic skin disease. Until today, only the combination of rifampin/streptomycin is used to treat buruli ulcer. However, this therapy is ineffective and expensive. Here, we report new findings that suggest pharmaceutical formulations such as rifapentine, in combination with…

Buruli ulcerChlamydia trachomatismedicine.disease_causeAzithromycinBiochemistryMicrobiologychemistry.chemical_compoundRare DiseasesPersonal hygieneClarithromycinDrug DiscoverymedicineAnimalsHumansMycolactoneBuruli UlcerPharmacologyTrachomabiologyMycobacterium ulceransbusiness.industryOrganic ChemistryVaccinationmedicine.diseasebiology.organism_classificationAnti-Bacterial AgentsTrachomachemistryMycobacterium ulceransImmunologyMolecular MedicineChlamydia trachomatisbusinessmedicine.drugCurrent medicinal chemistry
researchProduct

[Macrolides in the treatment of children with Mediterranean spotted fever].

2002

Till now there is not a gold standard therapy for Mediterranean spotted fever (MSF) in children. Standard treatment for MSF is the administration of tetracycline or chloramphenicol, however both these drugs can cause significant adverse effects in children (tetracyclines can cause staining of teeth, chloramphenicol severe hematological adverse events such as aplastic anemia, gray baby syndrome and hemolytic anemia in patients with the Mediterranean form of G6PD deficiency). We conducted two randomized clinical trials; the first compared clarithromycin versus chloramphenicol: mean time to defervescence was 36.7 +/- 18.1 h in the clarithromycin group and 47.1+/- 21.9 h in the chloramphenicol …

MaleAdolescentInfantAzithromycinBoutonneuse FeverAnti-Bacterial AgentsChloramphenicolTreatment OutcomeItalyTetracyclinesChild PreschoolClarithromycinHumansFemaleMacrolidesChildSicilyMediterranean spotted fever macrolidesRandomized Controlled Trials as TopicLe infezioni in medicina
researchProduct

Clarithromycin Versus Azithromycin in the Treatment of Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

2002

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (+/- standard deviation) was 46.2+/-36.4 h in the clarithromycin group and 39.3+/-31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromyci…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentErythromycinAzithromycinBoutonneuse FeverAzithromycinDrug Administration Schedulelaw.inventionRandomized controlled triallawClarithromycinClarithromycinInternal medicinemedicineHumansChildAntibacterial agentMediterranean spotted fever Clarithromycin azithromycinbusiness.industryInfantmedicine.diseaseAnti-Bacterial AgentsSurgerySpotted feverBoutonneuse feverRickettsia conoriiTreatment OutcomeInfectious DiseasesRickettsiosisChild PreschoolFemalebusinessmedicine.drugClinical Infectious Diseases
researchProduct